• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 26, 2025
Distillery Therapeutics

Small molecule inhibitor of KAT8 for esophageal cancer

Read More
BioCentury | Feb 26, 2025
Distillery Therapeutics

Inhibiting DUSP6 for colorectal cancer

Read More
BioCentury | Jan 28, 2025
Distillery Therapeutics

Inhibiting IRGQ for antitumor immunity in HCC

Read More
BioCentury | Jan 18, 2025
Product Development

2025 catalysts: New modality showdowns 

Genetic therapies compete in the same indications, as degraders come of age
Read More
BioCentury | Oct 9, 2024
Distillery Therapeutics

Targeting PRMT3 for HCC antitumor immunity

Read More
BioCentury | May 31, 2024
Distillery Therapeutics

NUDT1 PROTAC for MYC-driven cancers

Read More
BioCentury | Mar 12, 2022
Discovery & Translation

Translational highlights to watch for at AACR

BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference
Read More
BioCentury | Oct 15, 2021
Product Development

Oct. 14 Quick Takes: BeiGene, BMS spar as pharma seeks end to Abraxane deal

Plus: Culture, Anticancer, Rejuvenate, Regeneron and more
Read More
BioCentury | Jun 14, 2021
Emerging Company Profile

Anticancer Bioscience: applying synthetic lethality to MYC-driven cancers

Emerging Company Profile: Chengdu-based ACB joins a growing wave of next-gen synthetic lethality companies 
Read More
BioCentury | Apr 3, 2021
Product Development

Digging beyond the headlines at AACR 2021

Next-wave strategies for KRAS and TIGIT, allogeneic and personalized cell therapies, and targeted protein degraders
Read More
Items per page:
1 - 10 of 260